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LETTER TO THE EDITOR
Menorrhagia: an underappreciated problem in
pre-menopausal women with systemic lupus
erythematosus
Sir,
Anaemia is commonly seen in patients with sys-
temic lupus erythematosus (SLE) and may be the
result of haemolysis, drug treatment or anaemia of
chronic disease.1,2 However, in the general popula-
tion, the most common cause of anaemia is iron
deﬁciency secondary to menstrual blood loss.3
A previous European-wide study of >4000 other-
wise healthy pre-menopausal women found that
symptomatic heavy menstrual bleeding (HMB or
menorrhagia) aﬀected 27% of those surveyed.
This problem was further compounded by the fact
that 46% of symptomatic patients had never con-
sulted a healthcare professional regarding this prob-
lem.4 It is therefore surprising that, while 90% of
patients with SLE are female, little is known with
regard to the prevalence of menorrhagia.
In line with previously published studies, we con-
ducted a ‘female health questionnaire’-based survey
that sought to identify the rates of menorrhagia in
female patients with SLE attending the Lupus
Clinic at University College London Hospital,
UK. Menorrhagia was deﬁned as the presence of
two or more out of the following four symptoms (as
deﬁned in previously validated studies4,5): (a) ﬂood-
ing through clothes or bedding, (b) the need to
change sanitary products every 2 hours or less, (c)
the need to double sanitary protection and (d) pas-
sing large blood clots. In addition, patients were
asked to conﬁrm the number of menstrual cycles
experienced in the last 12 months and whether
they had previously sought help from a healthcare
professional for symptoms of menorrhagia. History
of anaemia and of previous iron supplementation
were also recorded.
A total of 116 patients fulﬁlling revised
American College of Rheumatology classiﬁcation
criteria6 participated in the study. Forty-six
patients were excluded in view of being post-meno-
pausal (with no menstrual periods reported in the
previous 12 months).
The remaining 70 pre-menopausal patients
showed typical characteristics of our clinic popula-
tion with mean (SD) age 37.8 7.1 years, mean
(SD) disease duration 16.8 7.2 years and ethni-
city 49% Caucasian, 20% Afro-Caribbean and
19% Asian. Although reduced rates of menstru-
ation and amenorrhoea have previously been
reported in SLE patients,7,8 these 70 patients
reported a mean (SD) of 10.7 (6.3) menstrual
cycles per year.
Menorrhagia (identiﬁed by at least two of the
four symptoms outlined above) was seen in 49%
of all pre-menopausal patients with lupus. This
is signiﬁcantly higher than the 27% reported at a
population level.4 Patients with menorrhagia
were signiﬁcantly more likely to report a history
of anaemia (p¼ 0.02) and previous treatment
with iron supplementation (p¼ 0.04). These
results are summarized in Table 1. Of the
patients with menorrhagia, 41% had not con-
sulted healthcare professionals regarding these
symptoms.
These ﬁndings suggest that menorrhagia is
common in women with SLE and is more prevalent
than in the general population, thus potentially rep-
resenting an underappreciated cause of iron deﬁ-
ciency and anaemia. Many of these patients do
not report symptoms of menorrhagia to healthcare
professionals. Therefore, it is important to consider
asking about this issue routinely, in particular in
patients with lupus who are anaemic without any
obviously apparent alternative cause.
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Table 1 Prevalence of symptoms of heavy menstrual bleeding and comparisons between symptomatic and non-symptomatic
patients
Total number of symptoms of HMB
% (n) of
pre-menopausal
patients (n¼ 70)
0 30% (21)
1 21% (15)
2 7% (5)
3 11% (8)
4 30% (21)
Questionnaire Results
All pre-
menopausal
patients
(n¼ 70)
Non-symptomatic:
patients with
<2/4 symptoms
(n¼ 36)
Symptomatic:
patients with
2 symptoms
(n¼ 34) p-value
Total number of menstrual periods in last 12 months SD 10.7 6.3 10.5 4.0 11.0 8.1 NS
Using OCP % (n) 9% (6) 11% (4) 6% (2) NS
Using implant/coil % (n) 7% (5) 3% (1) 12% (4) NS
History of anaemia % (n) 63% (44) 50% (18) 76% (26) 0.02*
Previous iron supplementation % (n) 71% (50) 61% (22) 82% (28) 0.04*
Oral % (n) 61% (43) 50% (18) 74% (25) 0.04*
Intravenous % (n) 19% (13) 19% (7) 18% (6) NS
SD, standard deviation; OCP, oral contraceptive pill; HMB, heavy menstrual bleeding *significant at <0.05.
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